EVEREST ORGANICS
|
|
BOM : 524790     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Mar 13,2025 |
Price(EOD): ₹ 260.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 252.20 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
EVEREST ORGANICS | 12.5% | -3.7% | 86.3% |
SUN PHARMACEUTICAL INDUSTRIES | 4.6% | -0.9% | 5.3% |
DIVIS LABORATORIES | 0.5% | -5.5% | 57.2% |
CIPLA | 0.2% | 0.6% | -3.3% |
TORRENT PHARMACEUTICALS | -0.4% | -1.5% | 14.8% |
DR REDDYS LABORATORIES | -2.2% | -8.6% | -13.4% |
MANKIND PHARMA | -4.9% | -10.2% | 0.3% |
ZYDUS LIFESCIENCES | -2.1% | -6.3% | -10.6% |
LUPIN | -3% | -4.7% | 17.3% |
FUNDAMENTAL ANALYSIS OF EVEREST ORGANICS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF EVEREST ORGANICS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-60.84
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -4.15 Cr
[Latest Qtr - Dec2024 - Standalone Results ] 5.51
P/B Calculated based on Book Value of Rs 45.84 Cr
[Latest Year - Mar2024 - Standalone Results ] 1.48
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
257% 303% 258% |
SHARE PRICE MOMENTUM OF EVEREST ORGANICS
EVEREST ORGANICS vs SENSEX
DEBT OF EVEREST ORGANICS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
1.26 1.12 0.83 1.07 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF EVEREST ORGANICS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF EVEREST ORGANICS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-4.53% 17.31% 54.08% 54.19% |
-19.91% 43.6% 657.24% 6611.76% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
EVEREST ORGANICS related INDICES
You may also like the below Video Courses
FAQ about EVEREST ORGANICS
Is EVEREST ORGANICS good for long term investment?
As on Mar 13,2025, the Fundamentals of EVEREST ORGANICS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of EVEREST ORGANICS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is EVEREST ORGANICS UnderValued or OverValued?
As on Mar 13,2025, EVEREST ORGANICS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of EVEREST ORGANICS ?
As on Mar 13,2025, the Intrinsic Value of EVEREST ORGANICS is Rs. 72.65 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 72.86
Fair Value [Median EV / Sales Model] : Rs. 64.49
Fair Value [Median Price / Sales Model] : Rs. 72.65
Estimated Median Fair Value of EVEREST ORGANICS : Rs. 72.65
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.